Inozyme Pharma Stock Probability of Future Stock Price Finishing Over 6.18
| INZY Stock | USD 2.92 0.13 4.26% |
Inozyme |
Inozyme Pharma Target Price Odds to finish over 6.18
The tendency of Inozyme Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 6.18 or more in 90 days |
| 2.92 | 90 days | 6.18 | about 1.65 |
Based on a normal probability distribution, the odds of Inozyme Pharma to move over $ 6.18 or more in 90 days from now is about 1.65 (This Inozyme Pharma probability density function shows the probability of Inozyme Stock to fall within a particular range of prices over 90 days) . Probability of Inozyme Pharma price to stay between its current price of $ 2.92 and $ 6.18 at the end of the 90-day period is about 81.07 .
Given the investment horizon of 90 days Inozyme Pharma has a beta of -0.62. This usually indicates as returns on the benchmark increase, returns on holding Inozyme Pharma are expected to decrease at a much lower rate. During a bear market, however, Inozyme Pharma is likely to outperform the market. Additionally Inozyme Pharma has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Inozyme Pharma Price Density |
| Price |
Predictive Modules for Inozyme Pharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Inozyme Pharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Inozyme Pharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Inozyme Pharma is not an exception. The market had few large corrections towards the Inozyme Pharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Inozyme Pharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Inozyme Pharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.78 | |
β | Beta against Dow Jones | -0.62 | |
σ | Overall volatility | 1.06 | |
Ir | Information ratio | -0.21 |
Inozyme Pharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Inozyme Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Inozyme Pharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Inozyme Pharma generated a negative expected return over the last 90 days | |
| Inozyme Pharma has high historical volatility and very poor performance | |
| Inozyme Pharma has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (71.17 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Inozyme Pharma currently holds about 151.48 M in cash with (70.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.77, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Inozyme Pharma has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Mereo BioPharma Group Shares Down 4.5 percent Heres What Happened |
Inozyme Pharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Inozyme Stock often depends not only on the future outlook of the current and potential Inozyme Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Inozyme Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 51.8 M | |
| Cash And Short Term Investments | 188.6 M |
Inozyme Pharma Technical Analysis
Inozyme Pharma's future price can be derived by breaking down and analyzing its technical indicators over time. Inozyme Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Inozyme Pharma. In general, you should focus on analyzing Inozyme Stock price patterns and their correlations with different microeconomic environments and drivers.
Inozyme Pharma Predictive Forecast Models
Inozyme Pharma's time-series forecasting models is one of many Inozyme Pharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Inozyme Pharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Inozyme Pharma
Checking the ongoing alerts about Inozyme Pharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Inozyme Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Inozyme Pharma generated a negative expected return over the last 90 days | |
| Inozyme Pharma has high historical volatility and very poor performance | |
| Inozyme Pharma has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (71.17 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Inozyme Pharma currently holds about 151.48 M in cash with (70.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.77, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Inozyme Pharma has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Mereo BioPharma Group Shares Down 4.5 percent Heres What Happened |
Additional Tools for Inozyme Stock Analysis
When running Inozyme Pharma's price analysis, check to measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.